The global crohn’s disease treatment market accounted for US$ 12.4 Bn in 2018 and burgeoning over the forthcoming years. Factors such as growing incidences of the crohn's disease, rising government initiatives for improving health care infrastructure, higher preference for biologics and anti-inflammatory drug therapies are some of the key factors propelling the market growth. However, lack of awareness regarding the disease among people is hampering the market growth. In addition, rising focus on emerging markets, such as India and China are opening new opportunities for the market growth.

 

Global crohn’s disease treatment market segmented on the basis of drug class, distribution channel and region.

 

For request sample: https://www.precisionbusinessinsights.com/request-sample?product_id=15661

 

Antibiotics Dominate the Global Crohn’s Disease Treatment Market

Based on drug class, global crohn’s disease treatment market segmented into monoclonal antibodies, immune system suppressants, anti-inflammatory drugs, anti-diarrheal, antibiotics and analgesics. Antibiotics segment held considerable market growth during estimated period. Crohn’s disease is an inflammatory bowel disease that occurs in the gastrointestinal tract. Antibiotics are medications used to treat bacterial infections. Antibiotics are designed to target specific bacterial populations and have different mechanisms of action to stop a bacterial population from growing or eradicate the bacteria. For people with crohn’s, antibiotics may help lower the amount and change the composition of bacteria in the intestines, which may relieve symptoms. Several antibiotic medications are used in to treat crohn’s diseases. For example, ciprofloxacin (Cipro) is prescribed to fight infection in people with crohn’s. Hence, the demand for antibiotics is rising in this market.

 

Asia Pacific Leads the Global Crohn’s Disease Treatment market

PBI’s global crohn’s disease treatment market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. According to regional analysis. Asia Pacific has witnessed considerable growth in this market owing to the large presence of patient population suffering with this disease, rapidly developing health care infrastructure coupled with increasing government support in providing good health care facilities. This region is one of the key markets for crohn’s disease treatment. Further, North America held significant market share during estimated period  due to existence of major pharmaceutical companies focusing on drug development in this region.

 

Strategic Approvals are the Key Strategies Adopted by Market Players

Global crohn’s disease treatment market further reveals that the key players increasingly adopting strategies such as launch of newer products, frequent product approvals, and long term alliance to improve market revenue share and gaining significant geographic presence across the region. For Instance, in 2016, the U.S. Food and Drug Administration (FDA) approved Inflectra developed by Celtrion, Inc. a Korean company, which is a biosimilar to Remicade patented by Janssen Biotech, Inc. for adult and pediatric patients suffering with Crohn’s disease and have inadequate response to conventional therapies.

 

Key player’s profiles in the report are Allergan, Inc. (U.S.), AbbVie Inc., (U.S.), Takeda Pharmaceutical Company Limited (Japan), Bayer AG (Switzerland), UCB S.A. (Belgium), Perrigo Company plc (Ireland)

Pfizer Inc. (US), Johnson & Johnson Services, Inc. (US), Ferring B.V. (Switzerland) and Celgene Corporation.

 

Precision Business Insights (PBI) in its report titled “Global Crohn’s Disease Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2025” assesses the market performance over seven years forecast period over 2019-2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period. Moreover, the report also includes the total revenue and volume for the market.

 

Detailed Segmentation

 

By Drug Class

• Monoclonal Antibodies
• Immune System Suppressants
• Anti-Inflammatory Drugs
• Anti-Diarrheal
• Antibiotics
• Analgesics

 

By Distribution Channel

• Retail Pharmacy
• Hospital Pharmacy
• Others

 

By Geography

• North America

• U.S
• Canada

• Europe

• Germany
• France
• U.K
• Italy
• Spain
• Russia
• Poland
• Rest of Europe

• Asia-Pacific

• Japan
• China
• India
• Australia & New Zealand
• ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
• South Korea
• Rest of Asia-Pacific

• Latin America

• Brazil
• Mexico
• Argentina
• Rest of Latin America

• Middle East and Africa (MEA)

• Gulf Cooperation Council (GCC) Countries
• Israel
• South Africa
• Rest of MEA

 

 

For more information: https://www.precisionbusinessinsights.com/market-reports/global-crohns-disease-treatment-market/

 

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customized market research services based on our client needs.

 

Kemp House,

152 – 160 City Road,

London EC1V 2NX

Email: sales@precisionbusinessinsights.com

Toll Free (US): +1-866-598-1553

Website @ https://www.precisionbusinessinsights.com